Mar 08, 2017 at 13:29 | Source:
Drug maker Dr Reddys Laboratories will be put to a crucial test in the second week of April as the company gears up for major USFDA audits at its facilities in Srikakulam located some 70 kms away from port city of Visakhapatnam.
Mar 08, 2017 at 09:25 | Source:
The US drug regulator cleared the companys investigational new drug application to begin phase two study of GSP 304 that will be used to treat chronic obstructive pulmonary disease.
Mar 08, 2017 at 09:16 | Source:
The pharma major announced a dividend of Rs 3.25 a share; it even received a nod from US FDA for a drug that is used to treat spasticity in relaxing muscles
Mar 08, 2017 at 08:14 | Source:
Tracking global cues as well as cautious stance ahead of key exit polls data, the Street may see tepid opening. Wockhardt will be on investors radar following the warning letter issued by US FDA for its US plant.
Mar 07, 2017 at 13:34 | Source: PTI
The company "announced today the launch of generic paxil CR extended release tablets, 12.5 mg, 25 mg and 37.5 mg, having received an approval from the United States Food and Drug Administration (FDA) earlier", Lupin said in a BSE filing.
Mar 06, 2017 at 13:35 | Source:
"The two observations cited are, in the opinion of the company, correctable ones in respect of which the company will file the necessary response within the stipulated period of 15 working days," Unichem said in a statement to stock exchanges.
Mar 03, 2017 at 13:59 | Source:
The court allowed the firm to make and sell Canmab, a cancer drug of the company. Stock was under pressure so far on the back of inspection reports. The management, earlier this morning, stated the inspections were expected as its dossiers were accepted by US FDA and EMA.
Mar 03, 2017 at 11:26 | Source: CNBC-TV18
Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.
Mar 02, 2017 at 14:39 | Source:
The US Food and Drug Administration (FDA) gave three observations under Form 483 for its formulations manufacturing facility at Baddi. These were related to pre-approval inspections for a specific product filed.
Mar 02, 2017 at 13:45 | Source: CNBC-TV18
Biotech company, Biocon will see two crucial inspections later this month and in early April. Companys manufacturing sites will come up for inspections by the European medicines agency later this month and next will be an inspection by the US FDA.
Messages on Fda »


Silver Member


Aarey Drugs  

fundamentally on profit side there is not much improvement as expenses are continuously rising , however top line is interesting and much more than the market cap of the company. debt looks to be well in control. right now focus being on domestic side so no FDA issues. It may prove to be another

10.13 PM Mar 23rd


New Member

0 Follower

Divis Laboratories  

divis has seen many such actions from us fda. it will overcome and rebound to 1200.

4.37 PM Mar 23rd


New Member



Lupin receives FDA approval for Generic TOBI Inhalation solution. Cheers!

3.29 PM Mar 23rd


Platinum Member


Divis Labs  

Divis Labs seeks meeting with US FDA, Might be going to re-call for Plant 1 inspection.

2.41 PM Mar 23rd


Halol plant wont be given fda clearence, same like divis

2.14 PM Mar 23rd


Platinum Member



US FDA facebook. You can call them as well. Type your message here (minimum 20

1.55 PM Mar 23rd


New Member

0 Follower

Sun Pharma  

its just matter of time there halol plant will get us fda go ahead

1.17 PM Mar 23rd


New Member


Divis Labs  

The blast will happen downwards not up , wait till FDA from European countrys take action following US

12.51 PM Mar 23rd


Silver Member


Divis Labs  

This will go up only if the US FDA issues are resolved. Until, then this scrip will trade sideways

11.55 AM Mar 23rd

Divis Labs  

divis refused the fda inspectors to enter the plant. divis is lying.

11.12 AM Mar 23rd

Follow us on
Available On